Literature DB >> 14501249

Prevention of urinary and anal incontinence: role of elective cesarean delivery.

Mira Lal1.   

Abstract

PURPOSE OF REVIEW: Currently, prophylactic elective cesarean to prevent incontinence is being promoted without robust evidence supporting it, this has created confusion among health personnel [corrected]. Past research centered on defining the damaging effect of vaginal birth on continence whilst the limited research on elective cesarean considered it protective. Cesarean delivery has economic, obstetric, gynecological and psychosocial consequences, but incontinence is not uncommon with a persistent morbidity. There is confusion among health personnel about advocating elective cesarean delivery to prevent incontinence. Reviewing current research would facilitate obstetric thinking. RECENT
FINDINGS: Multiplanar endosonography and three-dimensional magnetic resonance imaging scanning are reportedly better in delineating structural alterations in the continence mechanism following vaginal birth and could be applied to postcesarean incontinence. Incontinence can follow vaginal or elective cesarean delivery and the severity following either mode is comparable. Urinary incontinence can resolve, persist or start de novo and the primiparous prevalence is similar following cesarean or vaginal birth. Transient anal incontinence can manifest during pregnancy. Paradoxically, pelvic floor strengthening exercises are beneficial for pregnancy-related incontinence, yet urinary incontinence occurs in nulliparas notwithstanding a strong pelvic floor.
SUMMARY: Improved imaging techniques should promote a better understanding of postcesarean incontinence. Since severe incontinence can occur after elective cesarean, its reportedly preventative role deserves more scrutiny. When incontinence occurs without labor, it is transient or shows exercise-related improvement; the role of elective cesarean delivery seems tenuous and needs careful evaluation. Current evidence does not support the routine use of elective cesarean to prevent incontinence so the delivery mode should continue to be dictated by obstetric considerations.

Entities:  

Mesh:

Year:  2003        PMID: 14501249     DOI: 10.1097/00001703-200310000-00014

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  6 in total

1.  The impact of the active management of risk in pregnancy at term on birth outcomes: a randomized clinical trial.

Authors:  James M Nicholson; Samuel Parry; Aaron B Caughey; Sarah Rosen; Allison Keen; George A Macones
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

2.  Childbirth and pelvic floor dysfunction: an epidemiologic approach to the assessment of prevention opportunities at delivery.

Authors:  Divya A Patel; Xiao Xu; Angela D Thomason; Scott B Ransom; Julie S Ivy; John O L DeLancey
Journal:  Am J Obstet Gynecol       Date:  2006-03-30       Impact factor: 8.661

3.  The Role of Obstetric Factors, miRNA-30d and miRNA-181a in Postpartum Women with Pelvic Organ Prolapse.

Authors:  Wenyu Lin; Liqing Lin; Binhua Dong; Lihua Chen; Huifang Lei; Yuqin Gao; Yaojia Chen; Pengming Sun
Journal:  Risk Manag Healthc Policy       Date:  2020-10-28

4.  The association between increased use of labor induction and reduced rate of cesarean delivery.

Authors:  James M Nicholson; Peter Cronholm; Lisa C Kellar; Morghan H Stenson; George A Macones
Journal:  J Womens Health (Larchmt)       Date:  2009-11       Impact factor: 2.681

5.  Active management of risk in nulliparous pregnancy at term: association between a higher preventive labor induction rate and improved birth outcomes.

Authors:  James M Nicholson; Morghan H Stenson; Lisa C Kellar; Aaron B Caughey; George A Macones
Journal:  Am J Obstet Gynecol       Date:  2009-01-24       Impact factor: 8.661

Review 6.  A urogynecologist's view ofthe pelvic floor effects of vaginal delivery/cesarean section for the urologist.

Authors:  René Genadry
Journal:  Curr Urol Rep       Date:  2006-09       Impact factor: 2.862

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.